Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Total Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Total Non-Current Liabilities of $517.0 million for Q4 2025, up 28.06% on a QoQ basis from $403.7 million in Q4 2024, and up 28.06% year-over-year from $403.7 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Total Non-Current Liabilities data on file, last reported at $517.0 million in Q4 2025.

  • In Q4 2025, Total Non-Current Liabilities rose 28.06% year-over-year to $517.0 million; the TTM figure through Dec 2025 stood at $517.0 million (up 28.06% YoY), while the FY2025 annual figure was $517.0 million, up 35.21% from the prior year.
  • Total Non-Current Liabilities rose to $517.0 million in Q4 2025, from $403.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $517.0 million in Q4 2025 and bottomed at $59.9 million in Q4 2023.
  • A 3-year average of $326.9 million and a median of $403.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 574.17% — and 2025, when it grew 28.06%.
  • Year by year, Total Non-Current Liabilities stood at $59.9 million in 2023, then soared by 574.17% to $403.7 million in 2024, then grew by 28.06% to $517.0 million in 2025.
  • The last three Total Non-Current Liabilities figures came in at $517.0 million (Q4 2025), $403.7 million (Q4 2024), and $59.9 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 516.99 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 516.99 Mn
Dec 31, 2024 403.69 Mn
Dec 31, 2023 59.88 Mn